|
1
|
Lakoš Jukić I, Jerković Gulin S and
Marinović B: Blistering diseases in the mature patient. Clin
Dermatol. 36:231–238. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kasperkiewicz M: COVID-19 outbreak and
autoimmune bullous diseases: A systematic review of published
cases. J Am Acad Dermatol. 84:563–568. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chaudhari P and Marinkovich MP: What's new
in blistering disorders? Curr Allergy Asthma Rep. 7:255–263.
2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hofmann SC, Juratli HA and Eming R:
Bullous autoimmune dermatoses. J Dtsch Dermatol Ges. 16:1339–1358.
2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bickle K, Roark TR and Hsu S: Autoimmune
bullous dermatoses: A review. Am Fam Physician. 65:1861–1870.
2002.PubMed/NCBI
|
|
6
|
Patrício P, Ferreira C, Gomes MM and
Filipe P: Autoimmune bullous dermatoses: A review. Ann NY Acad Sci.
1173:203–210. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Egami S, Yamagami J and Amagai M:
Autoimmune bullous skin diseases, pemphigus and pemphigoid. J
Allergy Clin Immunol. 145:1031–1047. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kneisel A and Hertl M: Autoimmune bullous
skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol
Ges. 9:844–856; quiz 857. 2011.PubMed/NCBI View Article : Google Scholar : (In English,
German).
|
|
9
|
Kasperkiewicz M, Ellebrecht CT, Takahashi
H, Yamagami J, Zillikens D, Payne AS and Amagai M: Pemphigus. Nat
Rev Dis Primers. 3(17026)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pollmann R, Schmidt T, Eming R and Hertl
M: Pemphigus: A comprehensive review on pathogenesis, clinical
presentation and novel therapeutic approaches. Clin Rev Allergy
Immunol. 54:1–25. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Melchionda V and Harman KE: Pemphigus
vulgaris and pemphigus foliaceus: An overview of the clinical
presentation, investigations and management. Clin Exp Dermatol.
44:740–746. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Didona D, Maglie R, Eming R and Hertl M:
Pemphigus: Current and future therapeutic strategies. Front
Immunol. 10(1418)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Oktarina DA, van der Wier G, Diercks GF,
Jonkman MF and Pas HH: IgG-induced clustering of desmogleins 1 and
3 in skin of patients with pemphigus fits with the desmoglein
nonassembly depletion hypothesis. Br J Dermatol. 165:552–562.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Amber KT, Valdebran M and Grando SA:
Non-desmoglein antibodies in patients with pemphigus vulgaris.
Front Immunol. 9(1190)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yan L, Wang JM and Zeng K: Association
between HLA-DRB1 polymorphisms and pemphigus vulgaris: A
meta-analysis. Br J Dermatol. 167:768–777. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sultan AS, Villa A, Saavedra AP, Treister
NS and Woo SB: Oral mucous membrane pemphigoid and pemphigus
vulgaris-a retrospective two-center cohort study. Oral Dis.
23:498–504. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mustafa MB, Porter SR, Smoller BR and
Sitaru C: Oral mucosal manifestations of autoimmune skin diseases.
Autoimmun Rev. 14:930–951. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rashid H, Lamberts A, Diercks GFH, Pas HH,
Meijer JM, Bolling MC and Horváth B: Oral lesions in autoimmune
bullous diseases: An Overview of clinical characteristics and
diagnostic algorithm. Am J Clin Dermatol. 20:847–861.
2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Carvalho AA, Santos Neto DAD, Carvalho
MADR, Eleutério SJP and Xavier AREO: Neonatal pemphigus in an
infant born to a mother with pemphigus vulgaris: A case report. Rev
Paul Pediatr. 37:130–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Panko J, Florell SR, Hadley J, Zone J,
Leiferman K and Vanderhooft S: Neonatal pemphigus in an infant born
to a mother with serologic evidence of both pemphigus vulgaris and
gestational pemphigoid. J Am Acad Dermatol. 60:1057–1062.
2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Amer YB and Al Ajroush W: Pemphigus
vulgaris in a neonate. Ann Saudi Med. 27:453–455. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Huang YH, Wang SH, Kuo TT and Chi CC:
Pemphigus vegetans occurring in a split-thickness skin graft.
Dermatol Surg. 31:240–243. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sillevis Smitt JH, Mulder TJ, Albeda FW
and Van Nierop JC: Pemphigus vegetans in a child. Br J Dermatol.
127:289–291. 1992.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jain V, Jindal N and Imchen S: Localized
pemphigus vegetans without mucosal involvement. Indian J Dermatol.
59(210)2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Son YM, Kang HK, Yun JH, Roh JY and Lee
JR: The Neumann type of pemphigus vegetans treated with combination
of dapsone and steroid. Ann Dermatol. 23 (Suppl 3):S310–S313.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Peterman CM, Vadeboncoeur S, Schmidt BA
and Gellis SE: Pediatric pemphigus herpetiformis: Case report and
review of the literature. Pediatr Dermatol. 34:342–346.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Shimizu Y, Wakabayashi K, Hayashi Y, Hara
K, Aoyama R, Niimi T, Tomino Y, Wada R, Hata M and Suzuki Y: MPGN
type 3 associated with pemphigus herpetiformis mimicking PGNMID and
dermatitis herpetiformis. Case Rep Nephrol Dial. 9:15–24.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mihai S and Sitaru C: Immunopathology and
molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med.
11:462–481. 2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Aoki V, Sousa JX Jr, Fukumori LM, Périgo
AM, Freitas EL and Oliveira ZN: Direct and indirect
immunofluorescence. An Bras Dermatol. 85:490–500. 2010.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
30
|
Mihályi L, Kiss M, Dobozy A, Kemény L and
Husz S: Clinical relevance of autoantibodies in patients with
autoimmune bullous dermatosis. Clin Dev Immunol.
2012(369546)2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Saschenbrecker S, Karl I, Komorowski L,
Probst C, Dähnrich C, Fechner K, Stöcker W and Schlumberger W:
Serological diagnosis of autoimmune bullous skin diseases. Front
Immunol. 10(1974)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Abasq C, Mouquet H, Gilbert D, Tron F,
Grassi V, Musette P and Joly P: ELISA testing of anti-desmoglein 1
and 3 antibodies in the management of pemphigus. Arch Dermatol.
145:529–535. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mortazavi H, Shahdi M, Amirzargar AA,
Naraghi ZS, Valikhani M, Daneshpazhooh M, Vasheghani-Farahani A,
Sedaghat M and Chams-Davatchi C: Desmoglein ELISA in the diagnosis
of pemphigus and its correlation with the severity of pemphigus
vulgaris. Iran J Allergy Asthma Immunol. 8:53–56. 2009.PubMed/NCBI
|
|
34
|
Tampoia M, Giavarina D, Di Giorgio C and
Bizzaro N: Diagnostic accuracy of enzyme-linked immunosorbent
assays (ELISA) to detect anti-skin autoantibodies in autoimmune
blistering skin diseases: A systematic review and meta-analysis.
Autoimmun Rev. 12:121–126. 2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Naseer SY, Seiffert-Sinha K and Sinha AA:
Detailed profiling of anti-desmoglein autoantibodies identifies
anti-Dsg1 reactivity as a key driver of disease activity and
clinical expression in pemphigus vulgaris. Autoimmunity.
48:231–241. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Di Zenzo G, Di Lullo G, Corti D, Calabresi
V, Sinistro A, Vanzetta F, Didona B, Cianchini G, Hertl M, Eming R,
et al: Pemphigus autoantibodies generated through somatic mutations
target the desmoglein-3 cis-interface. J Clin Invest.
122:3781–3790. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lakshmi MJD, Jaisankar TJ, Rajappa M,
Thappa DM, Chandrashekar L, Divyapriya D, Munisamy M and Revathy G:
Correlation of antimuscarinic acetylcholine receptor antibody
titers and antidesmoglein antibody titers with the severity of
disease in patients with pemphigus. J Am Acad Dermatol. 76:895–902.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Heelan K, Mahar AL, Walsh S and Shear NH:
Pemphigus and associated comorbidities: A cross-sectional study.
Clin Exp Dermatol. 40:593–599. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Parameswaran A, Attwood K, Sato R,
Seiffert-Sinha K and Sinha AA: Identification of a new disease
cluster of pemphigus vulgaris with autoimmune thyroid disease,
rheumatoid arthritis and type I diabetes. Br J Dermatol.
172:729–738. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Almugairen N, Hospital V, Bedane C,
Duvert-Lehembre S, Picard D, Tronquoy AF, Houivet E, D'incan M and
Joly P: Assessment of the rate of long-term complete remission off
therapy in patients with pemphigus treated with different regimens
including medium- and high-dose corticosteroids. J Am Acad
Dermatol. 69:583–588. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Satyanarayanasetty D, Pawar K, Nadig P and
Haran A: Multiple adverse effects of systemic corticosteroids: A
case report. J Clin Diagn Res. 9:FD01–FD2. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ahmed AR, Kaveri S and Spigelman Z:
Long-term remissions in recalcitrant pemphigus vulgaris. N Engl J
Med. 373:2693–2694. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Beissert S, Werfel T, Frieling U, Böhm M,
Sticherling M, Stadler R, Zillikens D, Rzany B, Hunzelmann N,
Meurer M, et al: A comparison of oral methylprednisolone plus
azathioprine or mycophenolate mofetil for the treatment of
pemphigus. Arch Dermatol. 142:1447–1454. 2006.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Amagai M, Ikeda S, Shimizu H, Iizuka H,
Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, et al:
Pemphigus study group. A randomized double-blind trial of
intravenous immunoglobulin for pemphigus. J Am Acad Dermatol.
60:595–603. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Higashihara T, Kawase M, Kobayashi M, Hara
M, Matsuzaki H, Uni R, Matsumura M, Etoh T and Takano H: Evaluating
the efficacy of double-filtration plasmapheresis in treating five
patients with drug-resistant pemphigus. Ther Apher Dial.
21:243–247. 2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Eming R and Hertl M: Immunoadsorption in
pemphigus. Autoimmunity. 39:609–616. 2006.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Du FH, Mills EA and Mao-Draayer Y:
Next-generation anti-CD20 monoclonal antibodies in autoimmune
disease treatment. Auto Immun Highlights. 8(12)2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wang HH, Liu CW, Li YC and Huang YC:
Efficacy of rituximab for pemphigus: A systematic review and
meta-analysis of different regimens. Acta Derm Venereol.
95:928–932. 2015.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Seyfizadeh N, Seyfizadeh N, Hasenkamp J
and Huerta-Yepez S: A molecular perspective on rituximab: A
monoclonal antibody for B cell non Hodgkin lymphoma and other
affections. Crit Rev Oncol Hematol. 97:275–290. 2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ahmed AR, Spigelman Z, Cavacini LA and
Posner MR: Treatment of pemphigus vulgaris with rituximab and
intravenous immune globulin. N Engl J Med. 355:1772–1779.
2006.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Schmidt E, Goebeler M and Zillikens D:
Rituximab in severe pemphigus. Ann N Y Acad Sci. 1173:683–691.
2009.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chiu HY, Chang CY, Hsiao CH and Wang LF:
Concurrent cytomegalovirus and herpes simplex virus infection in
pemphigus vulgaris treated with rituximab and prednisolone. Acta
Derm Venereol. 93:200–201. 2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wei KC, Chen W, Tang PL and Huang YT:
Pneumocystis jirovecii pneumonia infection in pemphigus patients
treated with rituximab: An observational nationwide epidemiological
study in Taiwan. Eur J Dermatol. 28:713–715. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Amber KT, Kodiyan J, Bloom R and Hertl M:
The controversy of hepatitis C and rituximab: A multidisciplinary
dilemma with implications for patients with pemphigus. Indian J
Dermatol Venereol Leprol. 82:182–183. 2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Frampton JE: Rituximab: A review in
pemphigus vulgaris. Am J Clin Dermatol. 21:149–156. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Rapp M, Pentland A and Richardson C:
Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs
Dermatol. 17:1338–1339. 2018.PubMed/NCBI
|
|
57
|
Ellebrecht CT, Choi EJ, Allman DM, Tsai
DE, Wegener WA, Goldenberg DM and Payne AS: Subcutaneous
veltuzumab, a humanized anti-CD20 antibody, in the treatment of
refractory pemphigus vulgaris. JAMA Dermatol. 150:1331–1335.
2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Vinay K, Kanwar AJ, Mittal A, Dogra S,
Minz RW and Hashimoto T: Intralesional rituximab in the treatment
of refractory oral pemphigus vulgaris. JAMA Dermatol. 151:878–882.
2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Paolino G, Didona D, Magliulo G, Iannella
G, Didona B, Raffaele S, Moliterni E, Donati M, Ciofalo A, Granata
G, et al: Paraneoplastic pemphigus: Insight into the autoimmune
pathogenesis, clinical features and therapy. Int J Mol Sci.
18(2532)2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Tsuchisaka A, Numata S, Teye K, Natsuaki
Y, Kawakami T, Takeda Y, Wang W, Ishikawa K, Goto M, Koga H, et al:
Epiplakin is a paraneoplastic pemphigus autoantigen and related to
bronchiolitis obliterans in Japanese patients. J Investig Dermatol.
136:399–408. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Czernik A, Camilleri M, Pittelkow MR and
Grando SA: Paraneoplastic autoimmune multiorgan syndrome: 20 years
after. Int J Dermatol. 50:905–914. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wade MS and Black MM: Paraneoplastic
pemphigus: A brief update. Australas J Dermatol. 46:1–8; quiz 9-10.
2005.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Martel P, Loiseau P, Joly P, Busson M,
Lepage V, Mouquet H, Courville P, Flageul B, Charron D, Musette P,
et al: Paraneoplastic pemphigus is associated with the DRB1*03
allele. J Autoimmun. 20:91–95. 2003.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Kim JH and Kim SC: Paraneoplastic
pemphigus: Paraneoplastic autoimmune disease of the skin and
mucosa. Front Immunol. 10(1259)2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Healy WJ, Peters S and Nana-Sinkam SP: A
middle-aged man presenting with unexplained mucosal erosions and
progressive dyspnoea. BMJ Case Rep.
2015(bcr2014208677)2015.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mar WA, Glaesser R, Struble K,
Stephens-Groff S, Bangert J and Hansen RC: Paraneoplastic pemphigus
with bronchiolitis obliterans in a child. Pediatr Dermatol.
20:238–242. 2003.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Wieczorek M and Czernik A: Paraneoplastic
pemphigus: A short review. Clin Cosmet Investig Dermatol.
9:291–295. 2016.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Cummins DL, Mimouni D, Tzu J, Owens N,
Anhalt GJ and Meyerle JH: Lichenoid paraneoplastic pemphigus in the
absence of detectable antibodies. J Am Acad Dermatol. 56:153–159.
2007.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hashimoto T, Amagai M, Watanabe K,
Chorzelski TP, Bhogal BS, Black MM, Stevens HP, Boorsma DM, Korman
NJ, Gamou S, et al: Characterization of paraneoplastic pemphigus
autoantigens by immunoblot analysis. J Invest Dermatol.
104:829–834. 1995.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Frew JW and Murrell DF: Current management
strategies in paraneoplastic pemphigus (paraneoplastic autoimmune
multiorgan syndrome). Dermatol Clin. 29:607–612. 2011.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Lee A, Sandhu S, Imlay-Gillespie L,
Mulligan S and Shumack S: Successful use of Bruton's kinase
inhibitor, ibrutinib, to control paraneoplastic pemphigus in a
patient with paraneoplastic autoimmune multiorgan syndrome and
chronic lymphocytic leukaemia. Australas J Dermatol. 58:e240–e242.
2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Hohwy T, Bang K, Steiniche T, Peterslund
NA and d'Amore F: Alemtuzumab-induced remission of both severe
paraneoplastic pemphigus and leukaemic bone marrow infiltration in
a case of treatment-resistant B-cell chronic lymphocytic leukaemia.
Eur J Haematol. 73:206–209. 2004.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Gu L and Ye S: Tocilizumab cannot prevent
the development of bronchiolitis obliterans in patients with
Castleman disease-associated paraneoplastic pemphigus. J Clin
Rheumatol. 25:e77–e78. 2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
James KA, Culton DA and Diaz LA: Diagnosis
and clinical features of pemphigus foliaceus. Dermatol Clin.
29:405–412, viii. 2011.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Bastuji-Garin S, Souissi R, Blum L, Turki
H, Nouira R, Jomaa B, Zahaf A, Ben Osman A, Mokhtar I, Fazaa B, et
al: Comparative epidemiology of pemphigus in Tunisia and France:
Unusual incidence of pemphigus foliaceus in young Tunisian women. J
Invest Dermatol. 104:302–305. 1995.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Shirakata Y, Amagai M, Hanakawa Y,
Nishikawa T and Hashimoto K: Lack of mucosal involvement in
pemphigus foliaceus may be due to low expression of desmoglein 1. J
Invest Dermatol. 110:76–78. 1998.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Abida O, Kallel-Sellami M, Joly P, Ben
Ayed M, Zitouni M, Masmoudi A, Mokni M, Fezzaa B, Ben Osman A,
Kammoun MR, et al: Franco-Tunisian group of survey and research on
pemphigus. Anti-desmoglein 1 antibodies in healthy related and
unrelated subjects and patients with pemphigus foliaceus in endemic
and non-endemic areas from Tunisia. J Eur Acad Dermatol Venereol.
23:1073–1078. 2009.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Matkaluk RM and Bailin PL:
Penicillamine-induced pemphigus foliaceus. A fatal outcome. Arch
Dermatol. 117:156–157. 1981.PubMed/NCBI
|
|
79
|
Aoki V, Millikan RC, Rivitti EA,
Hans-Filho G, Eaton DP, Warren SJ, Li N, Hilario-Vargas J, Hoffmann
RG and Diaz LA: Cooperative Group for Fogo Selvagem Research.
Environmental risk factors in endemic pemphigus foliaceus (fogo
selvagem). J Investig Dermatol Symp Proc. 9:34–40. 2004.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Dalla-Costa R, Pincerati MR, Beltrame MH,
Malheiros D and Petzl-Erler ML: Polymorphisms in the 2q33 and 3q21
chromosome regions including T-cell coreceptor and ligand genes may
influence susceptibility to pemphigus foliaceus. Hum Immunol.
71:809–817. 2010.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Bruckner N, Katz RA and Hood AF: Pemphigus
foliaceus resembling eruptive seborrheic keratoses. Arch Dermatol.
116:815–816. 1980.PubMed/NCBI
|
|
82
|
Jacyk WK and Simson IW: Pemphigus
erythematosus resembling multiple seborrheic keratoses. Arch
Dermatol. 126:543–544. 1990.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Metry DW, Hebert AA and Jordon RE:
Nonendemic pemphigus foliaceus in children. J Am Acad Dermatol.
46:419–422. 2002.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Gomi H, Kawada A, Amagai M and Matsuo I:
Pemphigus erythematosus: Detection of anti-desmoglein-1 antibodies
by ELISA. Dermatology. 199:188–189. 1999.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Qaqish BF, Prisayanh P, Qian Y, Andraca E,
Li N, Aoki V, Hans-Filho G, dos Santos V, Rivitti EA and Diaz LA:
Cooperative Group on Fogo Selvagem Research. Development of an
IgG4-based predictor of endemic pemphigus foliaceus (fogo
selvagem). J Invest Dermatol. 129:110–118. 2009.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Schmidt E, Dähnrich C, Rosemann A, Probst
C, Komorowski L, Saschenbrecker S, Schlumberger W, Stöcker W,
Hashimoto T, Bröcker EB, et al: Novel ELISA systems for antibodies
to desmoglein 1 and 3: Correlation of disease activity with serum
autoantibody levels in individual pemphigus patients. Exp Dermatol.
19:458–463. 2010.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Sar-Pomian M, Kurzeja M, Rudnicka L and
Olszewska M: The value of trichoscopy in the differential diagnosis
of scalp lesions in pemphigus vulgaris and pemphigus foliaceus. An
Bras Dermatol. 89:1007–1012. 2014.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sami N, Qureshi A and Ahmed AR: Steroid
sparing effect of intravenous immunoglobulin therapy in patients
with pemphigus foliaceus. Eur J Dermatol. 12:174–178.
2002.PubMed/NCBI
|
|
89
|
Sawamura S, Kajihara I, Makino K, Makino
T, Fukushima S, Jinnin M, Oyama B, Hashimoto T and Ihn H: Systemic
lupus erythematosus associated with myasthenia gravis, pemphigus
foliaceus and chronic thyroiditis after thymectomy. Australas J
Dermatol. 58:e120–e122. 2017.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Kridin K, Patel PM, Jones VA, Cordova A
and Amber KT: IgA pemphigus: A systematic review. J Am Acad
Dermatol. 82:1386–1392. 2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Düker I, Schaller J, Rose C, Zillikens D,
Hashimoto T and Kunze J: Subcorneal pustular dermatosis–type IgA
pemphigus with autoantibodies to desmocollins 1, 2, and 3. Arch
Dermatol. 145:1159–1162. 2009.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Watts PJ and Khachemoune A: Subcorneal
pustular dermatosis: A review of 30 years of progress. Am J Clin
Dermatol. 17:653–671. 2016.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Kuan YZ, Chiou HT, Chang HC, Chan HL and
Kuo TT: Intraepidermal neutrophilic IgA dermatosis. J Am Acad
Dermatol. 22:917–919. 1990.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Adam Z, Krejcí M, Pour L, Feit J, Büchler
T and Hájek R: IgA pemphigus associated with monoclonal gammopathy
completely resolved after achievement of complete remission of
multiple myeloma with bortezomib, cyclophosphamide and
dexamethasone regimen. Wien Klin Wochenschr. 122:311–314.
2010.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Hirata Y, Abe R, Kikuchi K, Hamasaka A,
Shinkuma S, Ujiie H, Nomura T, Nishie W, Arita K and Shimizu H:
Intraepidermal neutrophilic IgA pemphigus successfully treated with
dapsone. Eur J Dermatol. 22:282–283. 2012.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Howell SM, Bessinger GT, Altman CE and
Belnap CM: Rapid response of IgA pemphigus of the subcorneal
pustular dermatosis subtype to treatment with adalimumab and
mycophenolate mofetil. J Am Acad Dermatol. 53:541–543.
2005.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Bliziotis I, Rafailidis P, Vergidis P and
Falagas ME: Regression of subcorneal pustular dermatosis type of
IgA pemphigus lesions with azithromycin. J Infect. 51:E31–E34.
2005.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Gruss C, Zillikens D, Hashimoto T, Amagai
M, Kroiss M, Vogt T, Landthaler M and Stolz W: Rapid response of
IgA pemphigus of subcorneal pustular dermatosis type to treatment
with isotretinoin. J Am Acad Dermatol. 43:923–926. 2000.PubMed/NCBI View Article : Google Scholar
|
